News Column

Researchers from University of Texas Describe Findings in Cancer Gene Therapy (Downregulation of miR-221/222 enhances sensitivity of breast cancer...

August 18, 2014



Researchers from University of Texas Describe Findings in Cancer Gene Therapy (Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3)

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting from Houston, Texas, by NewsRx journalists, research stated, "Aberrantly expressed microRNAs (miRNAs) are involved in breast tumorigenesis. It is still unclear if and how miRNAs-221/222 are implicated in breast cancer and the resistance to estrogen receptor modulator tamoxifen."

The news correspondents obtained a quote from the research from the University of Texas, "We investigated the roles and mechanisms of miR-221/222 in breast cancer cells, particularly in modulating response to tamoxifen therapy. MCF-7 and MDA-MB231 breast cancer cells were transfected with antisense oligonucleotides AS-miR-221 and AS-miR-222 and their expression of miR-221 and miR-222 was assessed. The correlation of miR-221/222 with tissue inhibitor of metalloproteinase-3 (TIMP3) expression was investigated by fluorescence quantitative PCR and western blotting analysis. The therapeutic sensitivity of these cells, transfected and untransfected, to tamoxifen was determined. Transfection of AS-miR-221 and AS-miR-222 dramatically inhibited expression of miR-221 and miR-222, respectively, in both MCF-7 and MDA-MB-231 cells (P < 0.05-0.01). Downregulation of miR-221/222 significantly increased the expression of TIMP3 compared with controls (P

According to the news reporters, the research concluded: "These findings suggest that upregulation of TIMP3 via inhibition of miRNA-221/222 could be a promising therapeutic approach for breast cancer."

For more information on this research see: Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Therapy, 2014;21(7):290-296. Cancer Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Cancer Gene Therapy - www.nature.com/cgt/)

Our news journalists report that additional information may be obtained by contacting R. Gan, Univ Texas MD Anderson Canc Center, Dept. of Lab Med, Houston, TX 77030, United States. Additional authors for this research include Y. Yang, X. Yang, L. Zhao, J. Lu and Q.H. Meng (see also Biotechnology).

Keywords for this news article include: Biotechnology, Texas, Drugs, Houston, Oncology, Stilbenes, Tamoxifen, United States, Breast Cancer, Women's Health, Benzene Derivatives, Cancer Gene Therapy, North and Central America, Hormones - Antineoplastics, Selective Estrogen Receptor Modulators

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters